Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Neoadjuvant Gemcitabine, Cisplatin, and Gefitinib for Stage IIIA N2 NSCLC
NCT00103051Phase 2Completed
- Sponsor
- European Organisation for Research and Treatment of Cancer
- Start
- Dec 2004
- Primary completion
- Nov 2005
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of gefitinib in non-small cell lung cancer (NSCLC), sponsored by European Organisation for Research and Treatment of Cancer. Started Dec 2004; status: completed.
02
Drugs
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT00103051.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00103051.